AI Article Synopsis
- PSMA PET/CT has become a key imaging technique for prostate cancer, offering advantages over traditional imaging methods and PSA serum levels, especially in monitoring treatment responses in patients with metastatic castration-resistant prostate cancer (mCRPC).
- A systematic search of medical literature revealed that PSMA PET imaging significantly improves sensitivity and specificity for detecting metastases, aiding in accurate staging and diagnosing distant spread of the disease.
- Ongoing prospective trials are expected to provide further evidence supporting the prognostic benefits of PSMA PET/CT in mCRPC, underscoring its growing importance in clinical practice.
Article Abstract
Objectives: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has gained a primary role in prostate cancer (PCa) imaging, overcoming conventional imaging and prostate-specific antigen (PSA) serum levels, and has recently emerged as a promising technique for monitoring therapy response in metastatic castration-resistant prostate cancer (mCRPC) patients treated with novel hormonal therapy, taxanes, and radioligand therapy (RLT). In this review, we aim to provide an overview of the most relevant aspects under study and future prospects related to the prognostic role of PSMA PET/CT in mCRPC.
Methods: A systematic literature search was performed in the following databases: MEDLINE, PubMed, and EMBASE databases. The study focused exclusively on English-language studies, excluding papers not pertinent to the topic.
Results: PSMA PET imaging offers a higher sensitivity and specificity than conventional imaging and provides accurate staging and efficient diagnosis of distant metastases. The data presented herein highlight the usefulness of PET in risk stratification, with a prognostic potential that can have a significant impact on clinical practice. Several prospective trials are ongoing and will shortly provide more evidence supporting the prognostic potential of PET PSMA data in this clinical scenario.
Conclusions: Current evidence proves the prognostic role of PSMA PET/CT in different settings, with raising relevance also in the context of mCRPC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11504290 | PMC |
| http://dx.doi.org/10.3390/biomedicines12102355 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!